Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1995 3
1996 1
1997 3
1998 8
1999 1
2000 5
2001 3
2002 10
2003 9
2004 8
2005 18
2006 18
2007 18
2008 20
2009 10
2010 18
2011 17
2012 21
2013 19
2014 26
2015 28
2016 17
2017 25
2018 21
2019 31
2020 27
Text availability
Article attribute
Article type
Publication date

Search Results

348 results
Results by year
Filters applied: . Clear all
Page 1
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Khoja L, et al. Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286. Ann Oncol. 2017. PMID: 28945858 Free article. Review.
Toward understanding and exploiting tumor heterogeneity.
Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CW, Siu L, Snyder A, Stower H, Swanton C, Verhaak RG, Zenklusen JC, Zuber J, Zucman-Rossi J. Alizadeh AA, et al. Nat Med. 2015 Aug;21(8):846-53. doi: 10.1038/nm.3915. Nat Med. 2015. PMID: 26248267 Free PMC article.
Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C, Lee JJ, Siu LL. Le Tourneau C, et al. J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. J Natl Cancer Inst. 2009. PMID: 19436029 Free PMC article. Review.
How liquid biopsies can change clinical practice in oncology.
Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. Siravegna G, et al. Ann Oncol. 2019 Oct 1;30(10):1580-1590. doi: 10.1093/annonc/mdz227. Ann Oncol. 2019. PMID: 31373349 Review.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Siu LL, et al. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. JAMA Oncol. 2019. PMID: 30383184 Free PMC article. Clinical Trial.
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.
Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, Siu LL. Oliva M, et al. Ann Oncol. 2019 Jan 1;30(1):57-67. doi: 10.1093/annonc/mdy507. Ann Oncol. 2019. PMID: 30462163 Free PMC article. Review.
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL. Kanjanapan Y, et al. Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15. Cancer. 2019. PMID: 30768786 Free article.
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL. Heinhuis KM, et al. JAMA Oncol. 2019 Nov 7;6(1):1-8. doi: 10.1001/jamaoncol.2019.3848. Online ahead of print. JAMA Oncol. 2019. PMID: 31697308 Free PMC article.
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Hobbs BP, et al. J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196. J Natl Cancer Inst. 2019. PMID: 30561713 Free PMC article. Review.
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Zandberg DP, et al. Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18. Eur J Cancer. 2019. PMID: 30576970 Free article. Clinical Trial.
348 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback